We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AllianceBernstein May AUM Rises on Inflows & Market Gains
Read MoreHide Full Article
AllianceBernstein Holding L.P. (AB - Free Report) announced assets under management (AUM) for May 2020. The company’s preliminary month-end AUM of $596 billion increased 3.5% from the prior month. Market appreciation and total firm-wide net inflows primarily drove the rise.
The reported monthly AUM also reflects $0.4 billion in outflows from AXA S.A.'s redemption of certain low-fee fixed income mandates.
At the end of the reported month, AllianceBernstein’s Equity AUM grew 5.2% sequentially to $222 billion. Fixed Income AUM also increased 2.3% from April 2020 to $307 billion. Others AUM (including certain multi-asset services and solutions, and some alternative investments) was up 3.1% from the prior month to $67 billion.
In terms of channel, month-end Institutions AUM of $280 billion was up 2.6% from April 2020. Retail AUM increased 5.2% on a sequential basis to $223 billion and Private Wealth AUM grew 2.2% to $93 billion.
Continued improvement in AUM is expected to support AllianceBernstein’s top line. So far this year, shares of the company have lost 12.2% compared with the industry’s decline of 0.3%.
Cohen & Steers (CNS - Free Report) reported preliminary AUM of $63.8 billion as of May 31, 2020, which increased 2.7% from the prior-month level. Market appreciation of $1.4 billion and net inflows of $428 million were partially offset by distributions of $199 million.
Franklin Resources (BEN - Free Report) announced preliminary AUM by its subsidiaries of $617.6 billion for May 2020. Results displayed a 3.04% increase from the $599.4 billion recorded as of April 30, 2020. Lower net outflows and a strong market performance led to the upsurge. However, the reported figure dropped 11.1% year on year.
Invesco’s (IVZ - Free Report) preliminary AUM of $1,142.5 billion at the end of May 2020 represents a 2.1% increase from the previous month. The rise was driven by favorable market returns, which led to an increase in AUM by $33 billion. However, FX lowered AUM by $1.4 billion.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
AllianceBernstein May AUM Rises on Inflows & Market Gains
AllianceBernstein Holding L.P. (AB - Free Report) announced assets under management (AUM) for May 2020. The company’s preliminary month-end AUM of $596 billion increased 3.5% from the prior month. Market appreciation and total firm-wide net inflows primarily drove the rise.
The reported monthly AUM also reflects $0.4 billion in outflows from AXA S.A.'s redemption of certain low-fee fixed income mandates.
At the end of the reported month, AllianceBernstein’s Equity AUM grew 5.2% sequentially to $222 billion. Fixed Income AUM also increased 2.3% from April 2020 to $307 billion. Others AUM (including certain multi-asset services and solutions, and some alternative investments) was up 3.1% from the prior month to $67 billion.
In terms of channel, month-end Institutions AUM of $280 billion was up 2.6% from April 2020. Retail AUM increased 5.2% on a sequential basis to $223 billion and Private Wealth AUM grew 2.2% to $93 billion.
Continued improvement in AUM is expected to support AllianceBernstein’s top line. So far this year, shares of the company have lost 12.2% compared with the industry’s decline of 0.3%.
AllianceBernstein currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Performance of Other Asset Managers
Cohen & Steers (CNS - Free Report) reported preliminary AUM of $63.8 billion as of May 31, 2020, which increased 2.7% from the prior-month level. Market appreciation of $1.4 billion and net inflows of $428 million were partially offset by distributions of $199 million.
Franklin Resources (BEN - Free Report) announced preliminary AUM by its subsidiaries of $617.6 billion for May 2020. Results displayed a 3.04% increase from the $599.4 billion recorded as of April 30, 2020. Lower net outflows and a strong market performance led to the upsurge. However, the reported figure dropped 11.1% year on year.
Invesco’s (IVZ - Free Report) preliminary AUM of $1,142.5 billion at the end of May 2020 represents a 2.1% increase from the previous month. The rise was driven by favorable market returns, which led to an increase in AUM by $33 billion. However, FX lowered AUM by $1.4 billion.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>